BioSpace News Archive

Business

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

Tetra Bio-Pharma Continues Forward into the Veterinary Ophthalmology Market by Entering into an Agreement with Drs. Cullen and Webb

October 14, 2017
·
6 min read
around-the-web

October 14, 2017
·
1 min read
Drug Development

BioPharm Executive: From the Bench to the Clinic

Alnylam’s victory with Patisiran in familial amyloid polyneuropathy (FAP) is significant for more than just the company and its patients.

October 14, 2017
·
1 min read
·
Karl Thiel
Business

BioPharm Executive: Career Track

Kare Schultz will become Teva’s fourth CEO in a decade, and its second outsider.

October 14, 2017
·
1 min read
·
Karl Thiel
Business

BioPharm Executive: Golden Handshakes

Halozyme’s Enhanze drug delivery technology just won it a $105 million upfront payment from Bristol-Myers Squibb.

October 14, 2017
·
1 min read
·
Karl Thiel
Biotech Bay

BioPharm Executive: Money Talk

Venture capital is hopping, attracted to some of the past several years’ successes.

October 14, 2017
·
1 min read
·
Karl Thiel
Policy

BioPharm Executive: Legal Briefs

What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development.

October 14, 2017
·
1 min read
·
Karl Thiel
FDA

BioPharm Executive: The Rockville Files

Officially, there have been four new chemical entities have been approved since our last issue.

October 14, 2017
·
1 min read
·
Karl Thiel